First International Meeting of the Thematic Centre for Immune Modulatory Therapies for Autoimmunity and Cancer (IMTAC) 13-14 June 2011, Ljusterö, Sweden.
- Published in:
- 2012
- By:
- Publication type:
- Report
Works matching IS 03407004 AND DT 2012 AND VI 61 AND IP 4
Results: 14
1
2
The aggressiveness of murine lymphomas selected in vivo by growth rate correlates with galectin-1 expression and response to cyclophosphamide.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 4, p. 469, doi. 10.1007/s00262-011-1114-3
- By:
- Publication type:
- Article
3
Therapeutic effect of intratumoral administration of DCs with conditional expression of combination of different cytokines.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 4, p. 573, doi. 10.1007/s00262-011-1198-9
- By:
- Publication type:
- Article
4
Recombinant human CD137L for cancer immunotherapy: effects of different fusions and linkers on its activity.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 4, p. 489, doi. 10.1007/s00262-011-1097-0
- By:
- Publication type:
- Article
5
A Th1 cytokine-enriched microenvironment enhances tumor killing by activated T cells armed with bispecific antibodies and inhibits the development of myeloid-derived suppressor cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 4, p. 497, doi. 10.1007/s00262-011-1116-1
- By:
- Publication type:
- Article
6
Immunological effects of Taxol and Adryamicin in breast cancer patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 4, p. 481, doi. 10.1007/s00262-011-1117-0
- By:
- Publication type:
- Article
7
Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 4, p. 535, doi. 10.1007/s00262-011-1121-4
- By:
- Publication type:
- Article
8
The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 4, p. 511, doi. 10.1007/s00262-011-1119-y
- By:
- Publication type:
- Article
9
Tipifarnib-mediated suppression of T-bet-dependent signaling pathways.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 4, p. 523, doi. 10.1007/s00262-011-1109-0
- By:
- Publication type:
- Article
10
The entirely carbohydrate immunogen Tn-PS A1 induces a cancer cell selective immune response and cytokine IL-17.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 4, p. 581, doi. 10.1007/s00262-012-1205-9
- By:
- Publication type:
- Article
11
Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 4, p. 453, doi. 10.1007/s00262-012-1216-6
- By:
- Publication type:
- Article
12
Intratumoral interleukin-2/agonist CD40 antibody drives CD4-independent resolution of treated-tumors and CD4-dependent systemic and memory responses.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 4, p. 549, doi. 10.1007/s00262-011-1120-5
- By:
- Publication type:
- Article
13
CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 4, p. 561, doi. 10.1007/s00262-011-1123-2
- By:
- Publication type:
- Article
14
Acknowledgement.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 4, p. 593, doi. 10.1007/s00262-012-1238-0
- Publication type:
- Article